Carbonyl Reductase 1 Plays a Significant Role in Converting Doxorubicin to Cardiotoxic Doxorubicinol in Mouse Liver, but the Majority of the Doxorubicinol-Forming Activity Remains Unidentified

Doxorubicin is a widely used cancer therapeutic, but its effectiveness is limited by cardiotoxic side effects. Evidence suggests cardiotoxicity is due not to doxorubicin, but rather its metabolite, doxorubicinol. Identification of the enzymes responsible for doxorubicinol formation is important in d...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Drug Metab Dispos
Autors principals: Breysse, Daniel H., Boone, Ryan M., Long, Cameron M., Merrill, Miranda E., Schaupp, Christopher M., White, Collin C., Kavanagh, Terrance J., Schmidt, Edward E., Merrill, Gary F.
Format: Artigo
Idioma:Inglês
Publicat: The American Society for Pharmacology and Experimental Therapeutics 2020
Matèries:
Articles
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC7011114/
https://ncbi.nlm.nih.gov/pubmed/31955137
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1124/dmd.119.089326
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars